LINE-1 as a therapeutic target for castration-resistant prostate cancer.

@article{Houd2018LINE1AA,
  title={LINE-1 as a therapeutic target for castration-resistant prostate cancer.},
  author={N. Hou{\'e}d{\'e} and P. Piazza and P. Pourquier},
  journal={Frontiers in bioscience},
  year={2018},
  volume={23},
  pages={
          1292-1309
        }
}
Prostate cancer is the third leading cause of death by cancer in men. Surgery or hormone deprivation usually contains the progression of the local forms of the disease. In metastatic situations, chemotherapy or second generation hormone therapies are used with an overall survival that never exceeds 36 months when tumors become resistant to castration. In the search for new alternatives, clinical trials with various classes of anticancer drugs have been performed, including chemotherapies… Expand
View on PubMed
bioscience.org
4 Citations
Background Citations
2

4 Citations

Citation Type

Citation Type

Reverse transcriptase inhibitors promote the remodeling of nuclear architecture and induce autophagy in prostate cancer cells.
  • 2
miR-425-5p suppresses tumorigenesis and DDP resistance in human-prostate cancer by targeting GSK3β and inactivating the Wnt/β-catenin signaling pathway
  • 3
Discovery of the Long Interspersed Nuclear Element-1 activation product [Open Reading Frame-1 (ORF1) protein] in human blood.
  • 3
Establishment of a recombinant Escherichia coli-induced piglet diarrhea model.
  • 5
  • PDF

References

SHOWING 1-10 OF 141 REFERENCES
Molecular alterations and emerging targets in castration resistant prostate cancer.
  • 50
Progress of molecular targeted therapies for prostate cancers.
  • 47
Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer.
  • 80
A comprehensive review of immunotherapies in prostate cancer.
  • 38
Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
  • 170
Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development
  • 24
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
  • 1,710
Immunotherapy for prostate cancer: False promises or true hope?
  • 17
A phase II trial evaluating the efficacy and safety of efavirenz in metastatic castration-resistant prostate cancer.
  • 27
Enzalutamide in metastatic prostate cancer before chemotherapy.
  • 1,823
  • PDF
...
1
2
3
4
5
...